Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $15.0 million
Deal Type : Agreement
MiNA Therapeutics Announces Equity Investment from Lilly
Details : Proceeds from the equity investment will be used to advance and expand MiNA’s internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
June 07, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : $15.0 million
Deal Type : Agreement